China Cord Blood Corp (NYSE:CO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $6.27, down by -1.1%, with a volume of 323,183 shares against an average volume for the last 3 months of 381,159.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
China Cord Blood Corp (NYSE:CO) stock is currently trading 13.4% below its 52-week-high, 52.93% above its 52-week-low. The 1-year stock price history is in the range of $4.1 – $7.24. China Cord Blood Corp (CO) has a price to earnings ratio of 28.63 versus Healthcare sector average of 26.64. CO stock price has outperformed the S&P 500 by 36.6%. The Medical Labs & Testing Services company is currently valued at $0.46 billion and its share price closed the last trading session at $6.27. The stock has a 50-day moving average of $6.19 and a 200-day moving average of $5.39.
China Cord Blood Corp (CO) current short interest stands at 0.08 million shares. It has increased by 20% from the same period of last month. Around 1% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.65 million shares, the number of days required to cover the short positions stand at 0.2 day.
CO reported last quarter earnings on June 18. The Medical Labs & Testing Services company announced earnings per share of $0.04 against a consensus Street estimate of $0.05, missing estimate by $0.01. This corresponds to a decrease of $0.02 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently one analysts that cover China Cord Blood Corp stock. Of those one, one has a Hold rating. On a consensus basis this yields to a Hold rating. The consensus target price stands at $6.75.
A recent analyst activity consisted of Roth Capital downgrading their Buy rating to Neutral on June 26. Roth Capital increased their price target on CO from $6.5 to $6.75. This corresponds to a 7.66% upside from the last closing price. On the date of report, the stock closed at $6.27.
Jefferies reiterated their Buy stance on March 18, and increased their price target on CO stock from $6 to $7. This corresponds to a 11.64% upside from the last closing price. On the date of report, the stock closed at $5.18.
China Cord Blood Corporation collects umbilical cord blood stem cells from newborn babies, and provides laboratory testing, hematopoietic stem cell processing, and stem cell storage services.